AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY19 results · Oct–Dec 2018
AstraZeneca Pharma India reported revenue from operations of ₹215.19 crore and net profit of ₹29.09 crore for Q3 FY19 (Oct–Dec 2018), on a standalone basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 215.19 | — | — | 161.36 | +33.4% |
| Other income | 3.50 | — | — | 3.35 | +4.2% |
| Total income | 218.69 | — | — | 164.72 | +32.8% |
| Profit before tax | 40.59 | — | — | 14.44 | +181.1% |
| Net profit for the period | 29.09 | — | — | 9.13 | +218.6% |
| EPS, basic (₹) | 11.64 | — | — | 3.65 | +218.6% |
| Net margin (%) | 13.5 | — | 5.7 |
Standalone
- Filed with BSE
- 07 Feb 2019, 16:08 IST
- Board meeting
- 06 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE